Critical Outcome Technologies Inc. is a clinical-stage biotechnology company that integrates artificial intelligence and machine learning into its drug discovery and development processes. The company’s proprietary platform enables rapid in silico screening, lead optimization and preclinical validation of small-molecule candidates, with a primary focus on oncology and infectious diseases.
Using its AI-enabled discovery engine, Critical Outcome Technologies has generated a pipeline of novel therapeutic candidates designed to address high-unmet-need targets. The lead asset, COTI-2, is a small-molecule reactivator of mutant p53 tumor suppressor protein and is currently being evaluated in a Phase I clinical trial. Additional preclinical programs are directed at drug-resistant bacterial infections and rare pediatric conditions.
Headquartered in Edmonton, Alberta, Canada, the company operates research and development facilities in North America to support its discovery, preclinical and clinical activities. Its multidisciplinary team combines expertise in computational chemistry, molecular biology and clinical development to advance programs through regulatory filings.
As a publicly traded entity on the OTCMKTS under the ticker COTQF, Critical Outcome Technologies aims to establish strategic partnerships and licensing collaborations to expand its footprint and accelerate the translation of its AI-driven pipeline into late-stage development and commercialization.
AI Generated. May Contain Errors.
Free COTQF Stock Alerts